Can a booster RSV shot shield the immunocompromised?
NCT ID NCT07768345
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This phase 3 trial is investigating whether giving a repeat dose of the RSVpreF vaccine to immunocompromised adults is safe and triggers a strong immune response. Participants, aged 18 and older, will receive one shot and be monitored for about a year. The study aims to find the best time interval for revaccination—around 1, 2, or 3 years after the first dose—to help protect this vulnerable group from severe RSV infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RSVpreF vaccine (a shot to help protect against respiratory syncytial virus)
- What this could lead to
- If successful, this could help determine the best timing for repeat RSV vaccinations in immunocompromised adults, potentially improving their protection against severe RSV disease.
- What could go wrong
- This is an early-stage study in a specific group, and the immune response may vary. As with any vaccine, there is a risk of side effects, and the results may not apply to all immunocompromised individuals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rochester Clinical Research
Rochester, New York, 14609, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One shot, two viruses? new mRNA vaccine targets RSV and hMPV
- New mRNA vaccine aims to shield against RSV
- Massive RSV vaccine study uses real-world data to see if shots prevent severe illness
- New RSV vaccine aims to shield adults from severe respiratory infection
- Scientists test RSV vaccine to boost immune memory
- New study tracks RSV in pregnant women and their babies